aTyr Pharma to Present at Upcoming Investor Conferences
Details of the presentations appear below:
Conference:
Date:
Time: 3
Location:
Conference: Piper Sandler 34th Annual Healthcare Conference
Date:
Time:
Location:
Conference: 5th Annual
Date:
Time:
Location: Virtual
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of each event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.
Contact:
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com
Source: aTyr Pharma, Inc.